8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Deciphering Tumor Niches: Lessons From Solid and Hematological Malignancies

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Knowledge about the hematopoietic niche has evolved considerably in recent years, in particular through in vitro analyzes, mouse models and the use of xenografts. Its complexity in the human bone marrow, in particular in a context of hematological malignancy, is more difficult to decipher by these strategies and could benefit from the knowledge acquired on the niches of solid tumors. Indeed, some common features can be suspected, since the bone marrow is a frequent site of solid tumor metastases. Recent research on solid tumors has provided very interesting information on the interactions between tumoral cells and their microenvironment, composed notably of mesenchymal, endothelial and immune cells. This review thus focuses on recent discoveries on tumor niches that could help in understanding hematopoietic niches, with special attention to 4 particular points: i) the heterogeneity of carcinoma/cancer-associated fibroblasts (CAFs) and mesenchymal stem/stromal cells (MSCs), ii) niche cytokines and chemokines, iii) the energy/oxidative metabolism and communication, especially mitochondrial transfer, and iv) the vascular niche through angiogenesis and endothelial plasticity. This review highlights actors and/or pathways of the microenvironment broadly involved in cancer processes. This opens avenues for innovative therapeutic opportunities targeting not only cancer stem cells but also their regulatory tumor niche(s), in order to improve current antitumor therapies.

          Related collections

          Most cited references194

          • Record: found
          • Abstract: found
          • Article: not found

          Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.

          The considerable therapeutic potential of human multipotent mesenchymal stromal cells (MSC) has generated markedly increasing interest in a wide variety of biomedical disciplines. However, investigators report studies of MSC using different methods of isolation and expansion, and different approaches to characterizing the cells. Thus it is increasingly difficult to compare and contrast study outcomes, which hinders progress in the field. To begin to address this issue, the Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy proposes minimal criteria to define human MSC. First, MSC must be plastic-adherent when maintained in standard culture conditions. Second, MSC must express CD105, CD73 and CD90, and lack expression of CD45, CD34, CD14 or CD11b, CD79alpha or CD19 and HLA-DR surface molecules. Third, MSC must differentiate to osteoblasts, adipocytes and chondroblasts in vitro. While these criteria will probably require modification as new knowledge unfolds, we believe this minimal set of standard criteria will foster a more uniform characterization of MSC and facilitate the exchange of data among investigators.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

            Therapeutic antibodies that block the programmed death-ligand 1 (PD-L1)/programmed death-1 (PD-1) pathway can induce robust and durable responses in patients with various cancers, including metastatic urothelial cancer (mUC) 1–5 . However, these responses only occur in a subset of patients. Elucidating the determinants of response and resistance is key to improving outcomes and developing new treatment strategies. Here, we examined tumours from a large cohort of mUC patients treated with an anti–PD-L1 agent (atezolizumab) and identified major determinants of clinical outcome. Response was associated with CD8+ T-effector cell phenotype and, to an even greater extent, high neoantigen or tumour mutation burden (TMB). Lack of response was associated with a signature of transforming growth factor β (TGF-β) signalling in fibroblasts, particularly in patients with CD8+ T cells that were excluded from the tumour parenchyma and instead found in the fibroblast- and collagen-rich peritumoural stroma—a common phenotype among patients with mUC. Using a mouse model that recapitulates this immune excluded phenotype, we found that therapeutic administration of a TGF-β blocking antibody together with anti–PD-L1 reduced TGF-β signalling in stromal cells, facilitated T cell penetration into the centre of the tumour, and provoked vigorous anti-tumour immunity and tumour regression. Integration of these three independent biological features provides the best basis for understanding outcome in this setting and suggests that TGF-β shapes the tumour microenvironment to restrain anti-tumour immunity by restricting T cell infiltration.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              On the Origin of Cancer Cells

              O WARBURG (1956)
                Bookmark

                Author and article information

                Contributors
                URI : https://loop.frontiersin.org/people/887252
                URI : https://loop.frontiersin.org/people/279732
                URI : https://loop.frontiersin.org/people/931009
                URI : https://loop.frontiersin.org/people/74669
                URI : https://loop.frontiersin.org/people/1184973
                URI : https://loop.frontiersin.org/people/1183615
                URI : https://loop.frontiersin.org/people/936607
                URI : https://loop.frontiersin.org/people/23455
                URI : https://loop.frontiersin.org/people/645615
                URI : https://loop.frontiersin.org/people/1458139
                Journal
                Front Immunol
                Front Immunol
                Front. Immunol.
                Frontiers in Immunology
                Frontiers Media S.A.
                1664-3224
                10 November 2021
                2021
                : 12
                : 766275
                Affiliations
                [1] 1 Centre National de la Recherche scientifique (CNRS) GDR3697, Micronit “Microenvironment of Tumor Niches” , Tours, France
                [2] 2 INSERM UMR1236, Rennes 1 University, Etablissement Français du Sang Bretagne , Rennes, France
                [3] 3 Cancéropole Grand-Ouest, NET network “Niches and Epigenetics of Tumors” , Nantes, France
                [4] 4 Saint-Louis Research Institute, University of Paris, EMiLy, INSERM U1160 , Paris, France
                [5] 5 The Organization for Partnerships in Leukemia (OPALE) Carnot Institute, The Organization for Partnerships in Leukemia , Paris, France
                [6] 6 Center for Research in Cancerology and Immunology Nantes-Angers (CRCINA), Signaling in Oncogenesis Angiogenesis and Permeability (SOAP), INSERM UMR1232, Centre National de la Recherche scientifique (CNRS) ERL600, Université de Nantes , Nantes, France
                [7] 7 Integrated Center for Oncology , St. Herblain, France
                [8] 8 Centre National de la Recherche scientifique (CNRS) UMR9005, SYS2DIAG-ALCEDIAG , Montpellier, France
                [9] 9 INSERM UMRS-MD1197, Paris-Saclay University, Paul-Brousse Hospital , Villejuif, France
                [10] 10 Cancer Research Center of Lyon (CRCL), CNRS UMR5286, INSERM U1052, Lyon 1 university, Lean Bérard Center , Lyon, France
                [11] 11 INSERM U1065, C3M, University of Côte d’Azur (UCA) , Nice, France
                [12] 12 Stress and Cancer Laboratory, Institut Curie, INSERM U830, Paris Sciences et Lettres (PSL) Research University, Team Babelized Ligue Nationale Contre le Cancer (LNCC) , Paris, France
                [13] 13 INSERM UMR1238 Phy-Os, Université de Nantes , Nantes, France
                [14] 14 Centre National de la Recherche scientifique (CNRS) ERL7001 LNOx, EA7501, Tours University , Tours, France
                [15] 15 Department of Biological Hematology, Tours University Hospital , Tours, France
                Author notes

                Edited by: Daniel F Legler, Biotechnology Institute Thurgau, Switzerland

                Reviewed by: Tanja Nicole Hartmann, University of Freiburg Medical Center, Germany; Barbara Molon, University of Padua, Italy; Takashi Nagasawa, Osaka University, Japan

                *Correspondence: Olivier Herault, olivier.herault@ 123456univ-tours.fr

                †These authors have contributed equally to this work and share first authorship

                This article was submitted to Cytokines and Soluble Mediators in Immunity, a section of the journal Frontiers in Immunology

                Article
                10.3389/fimmu.2021.766275
                8631445
                34858421
                b04d3316-cd1d-49e2-bbfc-1803887a9d37
                Copyright © 2021 Mancini, Balabanian, Corre, Gavard, Lazennec, Le Bousse-Kerdilès, Louache, Maguer-Satta, Mazure, Mechta-Grigoriou, Peyron, Trichet and Herault

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 28 August 2021
                : 25 October 2021
                Page count
                Figures: 1, Tables: 0, Equations: 0, References: 194, Pages: 14, Words: 6282
                Categories
                Immunology
                Mini Review

                Immunology
                microenvironment,cancer-associated fibroblasts (cafs),mesenchymal stem/stromal cells (mscs),cytokines and chemokines,energy/oxidative metabolism,mitochondrial transfer,angiogenesis,endothelial plasticity

                Comments

                Comment on this article

                scite_
                0
                0
                0
                0
                Smart Citations
                0
                0
                0
                0
                Citing PublicationsSupportingMentioningContrasting
                View Citations

                See how this article has been cited at scite.ai

                scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

                Similar content91

                Cited by11

                Most referenced authors5,142